March Bio has raised over $51 million to date inclusive of all dilutive and non-dilutive funding.
Founders
Sarah Hein
Company Description
March Biosciences is an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases. Its lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in Phase 1 trials in patients with refractory T-cell lymphoma and leukemia, with promising signals of efficacy and safety to date.